{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:17:52Z","timestamp":1775495872020,"version":"3.50.1"},"reference-count":43,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IRDR"],"published-print":{"date-parts":[[2020,5,31]]},"DOI":"10.5582\/irdr.2020.01028","type":"journal-article","created":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T22:04:41Z","timestamp":1590271481000},"page":"113-118","source":"Crossref","is-referenced-by-count":8,"title":["Fragile X associated neuropsychiatric disorders in a male without FXTAS"],"prefix":"10.5582","volume":"9","author":[{"given":"Ana Mar\u00eda","family":"Cabal-Herrera","sequence":"first","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA, USA."},{"name":"School of Medicine, Universidad del Valle, Cali, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilmar","family":"Saldarriaga-Gil","sequence":"additional","affiliation":[{"name":"School of Medicine, Universidad del Valle, Cali, Colombia."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jimena","family":"Salcedo-Arellano","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA, USA."},{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi J","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis Health, Sacramento, CA, USA."},{"name":"Department of Pediatrics, University of California Davis School of Medicine, Sacramento, CA, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hagerman RJ, Berry-Kravis E, Hazlett HC, Bailey DB, Moine H, Kooy RF, Tassone F, Gantois I, Sonenberg N, Mandel JL, Hagerman PJ. Fragile X syndrome. Nat Rev Dis Prim. 2017; 3:17065.","DOI":"10.1038\/nrdp.2017.65"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ciaccio C, Fontana L, Milani D, Tabano S, Miozzo M, Esposito S. Fragile X syndrome: a review of clinical and molecular diagnoses. Ital J Pediatr. 2017; 43:39.","DOI":"10.1186\/s13052-017-0355-y"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Debrey SM, Leehey MA, Klepitskaya O, Filley CM, Shah RC, Kluger B, Berry-Kravis E, Spector E, Tassone F, Hall DA. Clinical phenotype of adult fragile X gray zone allele carriers: a case series. Cerebellum. 2016; 15:623-631.","DOI":"10.1007\/s12311-016-0809-6"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hagerman RJ, Hagerman P. Fragile X-associated tremor\/ataxia syndrome - features, mechanisms and management. Nat Rev Neurol. 2016; 12:403-412.","DOI":"10.1038\/nrneurol.2016.82"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Allen EG, Glicksman A, Tortora N, Charen K, He W, Amin A, Hipp H, Shubeck L, Nolin SL, Sherman SL. FXPOI: Pattern of AGG interruptions does not show an association with age at amenorrhea among women with a premutation. Front Genet. 2018; 9: 292.","DOI":"10.3389\/fgene.2018.00292"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated neuropsychiatric disorders (FXAND). Front Psychiatry. 2018; 9:564.","DOI":"10.3389\/fpsyt.2018.00564"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Gossett A, Sansone S, Schneider A, Johnston C, Tassone F, Rivera SM, Seritan AL, Hessl D. Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome. Am J Med Genet B Neuropsychiatr Genet. 2016; 171:1139-1147.","DOI":"10.1002\/ajmg.b.32496"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Bourgeois JA, Cogswell JB, Hessl D, Zhang L, Ono MY, Tassone F, Farzin F, Brunberg JA, Grigsby J, Hagerman RJ. Cognitive, anxiety and mood disorders in the fragile X-associated tremor\/ataxia syndrome. Gen Hosp Psychiatry. 2007; 29:349-356.","DOI":"10.1016\/j.genhosppsych.2007.03.003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cordeiro L, Abucayan F, Hagerman R, Tassone F, Hessl D. Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands. Intractable Rare Dis Res. 2015; 4:123-130.","DOI":"10.5582\/irdr.2015.01029"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Grigsby J, Brega AG, Bennett RE, Bourgeois JA, Seritan AL, Goodrich GK, Hagerman RJ. Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning. Clin Neuropsychol. 2016; 30:944-959.","DOI":"10.1080\/13854046.2016.1185100"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Hunter JE, Allen EG, Abramowitz A, Rusin M, Leslie M, Novak G, Hamilton D, Shubeck L, Charen K, Sherman SL. No Evidence for a Difference in Neuropsychological Profile among Carriers and Noncarriers of the FMR1 Premutation in Adults under the Age of 50. Am J Hum Genet. 2008; 83:692-702.","DOI":"10.1016\/j.ajhg.2008.10.021"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Jiraanont P, Sweha SR, AlOlaby RR, Silva M, Tang HT, Durbin-Johnson B, Schneider A, Espinal GM, Hagerman PJ, Rivera SM, Hessl D, Hagerman RJ, Chutabhakdikul N, Tassone F. Clinical and molecular correlates in fragile X premutation females. eNeurologicalSci. 2017; 7:49-56.","DOI":"10.1016\/j.ensci.2017.04.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Franke P, Leboyer M, G\u00e4nsicke M, Weiffenbach O, Biancalana V, Cornillet-Lefebre P, Croquette MF, Froster U, Schwab SG, Poustka F, Hautzinger M, Maier W. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1. Psychiatry Res. 1998; 80:113-127.","DOI":"10.1016\/S0165-1781(98)00055-9"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Bourgeois JA, Seritan AL, Casillas EM, Hessl D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry. 2011; 72:175-182.","DOI":"10.4088\/JCP.09m05407blu"},{"key":"15","unstructured":"15. L. Seritan A, A. Bourgeois J, Schneider A, Mu Y, J. Hagerman R, V. Nguyen D. Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Curr Psychiatry Rev. 2013; 9:65-71."},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Roberts JE, Bailey Jr DB, Mankowski J, Ford A, Sideris J, Weisenfeld LA, Heath TM, Golden RN. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B:130-139.","DOI":"10.1002\/ajmg.b.30786"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Schneider A, Johnston C, Tassone F, Sansone S, Hagerman RJ, Ferrer E, Rivera SM, Hessl D. Broad autism spectrum and obsessive\u2013compulsive symptoms in adults with the fragile X premutation. Clin Neuropsychol. 2016; 30:929-943.","DOI":"10.1080\/13854046.2016.1189536"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Farzin F, Perry H, Hessl D, Loesch D, Cohen J, Bacalman S, Gane L, Tassone F, Hagerman PJ, Hagerman RJ. Autism spectrum disorders and attention-deficit\/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr. 2006; 27:S137-S144.","DOI":"10.1097\/00004703-200604002-00012"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Chonchaiya W, Au J, Schneider A, Hessl D, Harris SW, Laird M, Mu Y, Tassone F, Nguyen DV, Hagerman RJ. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet. 2012; 131:581-589.","DOI":"10.1007\/s00439-011-1106-6"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Summers SM, Cogswell J, Goodrich JE, Mu Y, Nguyen D V, Brass SD, Hagerman RJ. Fatigue and body mass index in the Fragile X premutation carrier. Fatigue Biomed Heal Behav. 2014; 2:64-72.","DOI":"10.1080\/21641846.2014.881155"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Movaghar A, Page D, Brilliant M, Baker MW, Greenberg J, Hong J, DaWalt LS, Saha K, Kuusisto F, Stewart R, Berry-Kravis E, Mailick MR. Data-driven phenotype discovery of FMR1 premutation carriers in a population-based sample. Sci Adv. 2019; 5:eaaw7195.","DOI":"10.1126\/sciadv.aaw7195"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Muzar Z, Adams PE, Schneider A, Hagerman RJ, Lozano R.Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases. Intractable rare Dis Res. 2014; 3:162-165.","DOI":"10.5582\/irdr.2014.01023"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Muzar Z, Lozano R, Schneider A, Adams PE, Faradz SMH, Tassone F, Hagerman RJ. Methadone use in a male with the FMRI premutation and FXTAS. Am J Med Genet Part A. 2015; 167:1354-1359.","DOI":"10.1002\/ajmg.a.37030"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Mart\u00ednez-Cerde\u00f1o V, Lechpammer M, Lott A, Schneider A, Hagerman R. Fragile X-associated tremor\/ataxia syndrome in a man in his 30s. JAMA Neurol. 2015; 72:1070-1073.","DOI":"10.1001\/jamaneurol.2015.1138"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Dorn MB, Mazzocco MM, Hagerman RJ. Behavioral and psychiatric disorders in adult male carriers of fragile X. J Am Acad Child Adolesc Psychiatry. 1994; 33:256-264.","DOI":"10.1097\/00004583-199402000-00015"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Santos E, Emeka-Nwonovo C, Wang JY, Schneider A, Tassone F, Hagerman P, Hagerman RJ. Developmental aspects of FXAND in a man with the FMR1 premutation. Mol Genet Genomic Med. 2020; 8:e1050.","DOI":"10.1002\/mgg3.1050"},{"key":"27","doi-asserted-by":"publisher","unstructured":"27. G Tan MM, S Dy JB, Salcedo-Arellano MJ, Tassone F, Hagerman RJ. Fragile X-Associated neuropsychiatric disorders: A case report. Future Neurol. 2019; 14. doi: 10.2217\/fnl-2018-0040","DOI":"10.2217\/fnl-2018-0040"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Schmitz-H\u00fcbsch T. Scale for the assessment and rating of ataxia (SARA). In book: Encyclopedia of Movement Disorders. 2010; pp.95-99.","DOI":"10.1016\/B978-0-12-374105-9.00534-7"},{"key":"29","unstructured":"29. Jankovic J, Tolosa E. Parkinson&apos;s Disease and Movement Disorders. 6th Editio. Jankovic J, Tolosa E, editors. Baltimore: Williams &amp; Wilkins; 2015."},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Saldarriaga W, Forero-Forero JV, Gonz\u00e1lez-Teshima LY, Fandi\u00f1o-Losada A, Isaza C, Tovar-Cuevas JR, Silva M, Choudhary NS, Tang HT, Aguilar-Gaxiola S, Hagerman RJ, Tassone F. Genetic cluster of fragile X syndrome in a Colombian district. J Hum Genet. 2018; 63:509-516.","DOI":"10.1038\/s10038-017-0407-6"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Hocking DR, Loesch DZ, Trost N, Bui MQ, Hammersley E, Francis D, Tassone F, Storey E. Total and regional white matter lesions are correlated with motor and cognitive impairments in carriers of the FMR1 premutation. Front Neurol. 2019; 10:832.","DOI":"10.3389\/fneur.2019.00832"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Brown SSG, Stanfield AC. Fragile X premutation carriers: A systematic review of neuroimaging findings. J Neurol Sci. 2015; 352:19-28.","DOI":"10.1016\/j.jns.2015.03.031"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Hall DA, Birch RC, Anheim M, J\u00f8nch AE, Pintado E, O&apos;Keefe J, Trollor JN, Stebbins GT, Hagerman RJ, Fahn S, Berry-Kravis E, Leehey MA. Emerging topics in FXTAS. J Neurodev Disord. 2014; 6:31.","DOI":"10.1186\/1866-1955-6-31"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Filley CM, Brown MS, Onderko K, Ray M, Bennett RE, Berry-Kravis E, Grigsby J. White matter disease and cognitive impairment in FMR1 premutation carriers. Neurology. 2015; 84:2146-2152.","DOI":"10.1212\/WNL.0000000000001612"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Wang JY, Hagerman RJ, Rivera SM. A multimodal imaging analysis of subcortical gray matter in fragile X premutation carriers. Mov Disord. 2013; 28:1278-1284.","DOI":"10.1002\/mds.25473"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Famula JL, McKenzie F, McLennan YA, Grigsby J, Tassone F, Hessl D, Rivera SM, Martinez-Cerde\u00f1o V, Hagerman RJ. Presence of middle cerebellar peduncle sign in FMR1 premutation carriers without tremor and ataxia. Front Neurol. 2018; 9:695.","DOI":"10.3389\/fneur.2018.00695"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Kogan CS, Turk J, Hagerman RJ, Cornish KM. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated tremor\/ataxia syndrome: A controlled study. Am J Med Genet Part B Neuropsychiatr Genet. 2008; 147B:859-872.","DOI":"10.1002\/ajmg.b.30685"},{"key":"38","unstructured":"38. Polussa J, Schneider A, Hagerman R. Molecular advances leading to treatment implications for fragile X premutation carriers. Brain Disord Ther. 2014; 3. pii: 1000119."},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Alfonso-Loeches S, Pascual-Lucas M, Blanco AM, Sanchez-Vera I, Guerri C. Pivotal role of TLR4 receptors in alcohol-induced neuroinflammation and brain damage. J Neurosci. 2010; 30:8285-8295.","DOI":"10.1523\/JNEUROSCI.0976-10.2010"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Loesch DZ, Sherwell S, Kinsella G, Tassone F, Taylor A, Amor D, Sung S, Evans A. Fragile X-associated tremor\/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet. 2012; 82:88-92.","DOI":"10.1111\/j.1399-0004.2011.01675.x"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Hessl D, Tassone F, Loesch DZ, <i>et al.<\/i> Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet Part B Neuropsychiatr Genet. 2005; 139B:115-121.","DOI":"10.1002\/ajmg.b.30241"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Winarni TI, Schneider A, Ghaziuddin N, Seritan A, Hagerman RJ. Psychosis and catatonia in fragile X: case report and literature review. Intractable Rare Dis Res. 2015; 4:139-146.","DOI":"10.5582\/irdr.2015.01028"},{"key":"43","unstructured":"43. Seritan A, Cogswell J, Grigsby J. Cognitive dysfunction in FMR1 premutation carriers. Curr Psychiatry Rev. 2013; 9:78-84."}],"container-title":["Intractable &amp; Rare Diseases Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/2\/9_2020.01028\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T03:39:27Z","timestamp":1592624367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/irdr\/9\/2\/9_2020.01028\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,31]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.5582\/irdr.2020.01028","relation":{},"ISSN":["2186-361X","2186-3644"],"issn-type":[{"value":"2186-361X","type":"electronic"},{"value":"2186-3644","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,31]]}}}